PL2882440T3 - Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa - Google Patents
Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfaInfo
- Publication number
- PL2882440T3 PL2882440T3 PL13748243T PL13748243T PL2882440T3 PL 2882440 T3 PL2882440 T3 PL 2882440T3 PL 13748243 T PL13748243 T PL 13748243T PL 13748243 T PL13748243 T PL 13748243T PL 2882440 T3 PL2882440 T3 PL 2882440T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitor
- pi3k
- optional
- alfa
- pharmaceutical combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680473P | 2012-08-07 | 2012-08-07 | |
| EP13748243.6A EP2882440B1 (en) | 2012-08-07 | 2013-08-05 | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| PCT/US2013/053619 WO2014025688A1 (en) | 2012-08-07 | 2013-08-05 | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2882440T3 true PL2882440T3 (pl) | 2019-07-31 |
Family
ID=48980368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13748243T PL2882440T3 (pl) | 2012-08-07 | 2013-08-05 | Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa |
Country Status (39)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2882440B1 (en) * | 2012-08-07 | 2019-02-27 | Novartis AG | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| CN112641787A (zh) | 2013-03-21 | 2021-04-13 | 诺华股份有限公司 | 包含B-Raf抑制剂和第二抑制剂的组合疗法 |
| WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| EP3392348A3 (en) * | 2014-06-16 | 2018-11-21 | Worldwide Innovative Network | Method for selecting personalized tri-therapy for cancer treatment |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
| CN107921026A (zh) * | 2015-08-28 | 2018-04-17 | 诺华股份有限公司 | 药物组合物包含(a)α‑同种型特异性PI3K抑制剂alpelisib(BYL719)和(b)AKT抑制剂,优选MK‑2206,afuresertib或uprosertib及其在治疗/预防癌症中的应用 |
| US10328065B2 (en) | 2015-08-28 | 2019-06-25 | Novartis Ag | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| MX387795B (es) * | 2016-06-03 | 2025-03-19 | Array Biopharma Inc | Combinaciones farmaceuticas. |
| WO2018051306A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| KR20240032157A (ko) | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
| WO2019026007A1 (en) * | 2017-08-03 | 2019-02-07 | Novartis Ag | THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR |
| HUE066335T2 (hu) | 2018-10-05 | 2024-07-28 | Annapurna Bio Inc | Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére |
| WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| GB2629956A (en) * | 2022-01-27 | 2024-11-13 | Univ Tohoku | Therapeutic agent for cancer |
| CA3257280A1 (en) | 2022-05-25 | 2023-11-30 | Msd International Gmbh | COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION |
| IL319792A (en) * | 2022-09-26 | 2025-05-01 | Mapkure Llc | Combinations of B-RAF inhibitor and anti-EGFR antibody for cancer treatment |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
| WO2025262686A1 (en) * | 2024-06-20 | 2025-12-26 | Ilan Paz | Devices, systems and methods for optimized, personalized administration of oral dosage forms |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| UA100979C2 (ru) | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| JP2013502236A (ja) | 2009-08-24 | 2013-01-24 | ジェネンテック， インコーポレイテッド | Ｋｒａｓ変異及びｒｔｋ発現レベルを検出することによるｂ−ｒａｆ阻害剤治療に対する細胞の感受性の決定 |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| WO2011046894A1 (en) * | 2009-10-12 | 2011-04-21 | Glaxosmithkline Llc | Combination |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| US20130209461A1 (en) * | 2010-11-08 | 2013-08-15 | Novartis Ag | Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| JP2014533273A (ja) | 2011-11-10 | 2014-12-11 | メモリアル スローン−ケタリング キャンサー センター | ２−アミノ−４Ｈ−ナフト［１，２−ｂ］ピラン−３−カルボニトリルを用いた卵巣がんの治療 |
| CN103917236A (zh) * | 2011-11-11 | 2014-07-09 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| EP2882440B1 (en) * | 2012-08-07 | 2019-02-27 | Novartis AG | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
-
2013
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 HK HK15110834.2A patent/HK1211831A1/xx unknown
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en not_active Ceased
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 EP EP19159506.5A patent/EP3574904B1/en active Active
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active Active
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-04 PH PH12015500246A patent/PH12015500246A1/en unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2882440T3 (pl) | Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa | |
| IL269045A (en) | Aptamers and uses thereof | |
| LT2841428T (lt) | Dnr-pk inhibitoriai | |
| EP2844637A4 (en) | SUBSTITUTED 3-HALOALLYLAMININHIBITORS OF SSAO AND USES THEREOF | |
| DK3293183T3 (da) | Hæmmerforbindelser | |
| EP2882534A4 (en) | ULTRASOUND THERMOCYCLER | |
| PT2802325T (pt) | Compostos anestésicos e métodos de utilização relacionados | |
| DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
| EP2930714A4 (en) | Singing voice synthesizing system and singing voice synthesizing method | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| EP2875051A4 (en) | ANTIBODIES AGAINST SIGLEC-15 | |
| SI2976106T1 (sl) | Kombinacijska terapija, ki vsebuje zaviralec B-Raf in drugi zaviralec | |
| BR112014031384A2 (pt) | métodos e sistemas | |
| EP2832855A4 (en) | NOVEL ANTI-SIGLEC-15 ANTIBODY | |
| BR112015005361A2 (pt) | inibidores de tirosina quinase de bruton | |
| BR112014033056A2 (pt) | inibidores da proteína quinase | |
| ME03084B (me) | Inhibiтori inhibiтora proteina apoptoze | |
| BR112014029718A2 (pt) | inibidores da proteína quinase | |
| EP2847201A4 (en) | 6-oxo-purin-phosphoribosyl INHIBITORS | |
| NL301064I2 (nl) | toltrazuril en gleptoferron | |
| EP2881444A4 (en) | Water-repellent and oil-repellent composition and articles therewith | |
| DK2943460T3 (da) | 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf | |
| HUE037085T2 (hu) | Karbamid vegyületek és enzim-inhibitorként történõ alkalmazásuk | |
| DK2805954T3 (da) | 7-substitueret hanfangichin b-derivat, og fremstillingsfremgangsmåde og anvendelse deraf |